Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort Study

BACKGROUND: The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) and dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trials have demonstrated significant kidney benefits with sodium-glucose cotransporter-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Tae Won, Atiquzzaman, Mohammad, Zheng, Yuyan, Smyth, Brendan, Jardine, Meg, Levin, Adeera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Clinical Research Quantitative
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791275/
https://www.ncbi.nlm.nih.gov/pubmed/36578697
http://dx.doi.org/10.1177/20543581221145068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791275/
https://www.ncbi.nlm.nih.gov/pubmed/36578697
http://dx.doi.org/10.1177/20543581221145068

Ejemplares similares